INTERPRETING FINDINGS WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION : COLLECTIVE VIEWS ON DATA FROM SEMINAL STUDIES TO PRESENT IN CLINICAL PRACTICE

1. Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada 2. Chairman, Department of Cardiology and Angiology I, University Heart Center Freiburg; Chairman, Department of Medical Intensive Care, University Clinic Freiburg, Freiburg, Germany 3. Associate Professor of Medicine, Director of Interventional Cardiology, Duke University Health System, Durham, North Carolina, USA 4. Professor of Medicine, Director, Duke Clinical Research Institute, Durham, North Carolina, USA 5. Department of Cardiovascular Medicine, University of Leuven, Leuven, Belgium

[1]  R. Cappato,et al.  Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study , 2016, Current medical research and opinion.

[2]  B. Gersh,et al.  Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. , 2016, JAMA.

[3]  A. Skanes,et al.  Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. , 2016, The Canadian journal of cardiology.

[4]  M. Tinetti,et al.  Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. , 2016, JAMA cardiology.

[5]  G. Breithardt,et al.  On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF , 2015, Circulation.

[6]  A. Camm,et al.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.

[7]  J. Beyer-Westendorf,et al.  Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[8]  S. Connolly,et al.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.

[9]  D. Singer,et al.  Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. , 2015, Journal of the American College of Cardiology.

[10]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[12]  G. Lip,et al.  Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. , 2015, European heart journal.

[13]  W. Frank Peacock,et al.  Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban , 2015, Clinical cardiology.

[14]  J. Hirsh,et al.  Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials , 2014, Thrombosis and Haemostasis.

[15]  J. Beyer-Westendorf,et al.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. , 2014, Blood.

[16]  David M. Smith,et al.  Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation , 2014, Current medical research and opinion.

[17]  D. Singer,et al.  Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.

[18]  W. Olson,et al.  Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients , 2014, Current medical research and opinion.

[19]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[21]  B. Gersh,et al.  Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry , 2013, Journal of the American Heart Association.

[22]  G. Lip,et al.  Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.

[23]  J. Eikelboom,et al.  Periprocedural management and approach to bleeding in patients taking dabigatran. , 2012, Circulation.

[24]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[25]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[26]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[27]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[28]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[29]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[30]  R. Hayward,et al.  Beyond the Randomized Clinical Trial the Role of Effectiveness Studies in Evaluating Cardiovascular Therapies the Achilles' Heel of Rcts Key Issues in Outcomes Research , 2022 .